Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Fallopian Tube Neoplasms 7Ovarian Neoplasms 6Breast Neoplasms 4Multiple Myeloma 3Lymphoma 3Sarcoma, Kaposi 2Neoplasms 2Multi-centric Castleman's Disease 2Leukemia 2Hodgkin Disease 2Triple Negative Breast Neoplasms 1Subcutaneous panniculitis-like T-cell lymphoma 1Sarcoma, Synovial 1Sarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Platinum-Refractory Fallopian Tube Carcinoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Lymphadenopathy 1

Interventions

Vincristine 4Prednisone 3MLN 8237 3Doxorubicin 3Cyclophosphamide 3temsirolimus 2romidepsin 2Specimen Handling 2Sirolimus 2Rituximab 2Lenalidomide 2Lactones 2Etoposide 2Depsipeptides 2Biopsy 2veliparib 1tipifarnib 1tazemetostat 1talimogene laherparepvec 1siplizumab 1pegaspargase 1molibresib 1merphos 1liposomal doxorubicin 1entinostat 1dexamethasone acetate 1dexamethasone 21-phosphate 1belinostat 1avelumab 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, T-Cell × liposomal doxorubicin × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡